/CNW/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA)...
– Both pivotal studies achieved primary endpoints of LS mean reduction in LDL-C on top of maximally tolerated lipid-modifying therapies with high statistical...
NewAmsterdam Pharma closes a public offering, raising approximately $452.6 million for its LDL-C lowering therapies.Quiver AI SummaryNewAmsterdam Pharma Company N.V. has completed its underwritten public...
NewAmsterdam Pharma announces $416.5 million public offering of ordinary shares and pre-funded warrants to support cardiovascular treatments.Quiver AI SummaryNewAmsterdam Pharma Company N.V., a clinical...
NewAmsterdam reports positive Phase 3 results for obicetrapib, showing significant LDL-C reduction and favorable safety profile compared to placebo.Quiver AI SummaryNewAmsterdam Pharma Company has reported...
NewAmsterdam Pharma grants 79,000 share options to new hires as employment inducement under its 2024 Inducement Plan.Quiver AI SummaryNewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical firm...
NewAmsterdam Pharma reports significant LDL-C and Lp(a) reductions with obicetrapib in Phase 3 trial, maintaining safety comparable to placebo.Quiver AI SummaryNewAmsterdam Pharma Company announced positive...
The company announced a stock sale to help fund operations.
The LSP Dementia Fund has held its final close at approximately EUR 260 million, at the hard cap and above its original target fund size of EUR 100 million...